ArticleTherapeutic advances in gastroenterology2024
Outcomes of treatment cessation after switching to subcutaneous vedolizumab treatment in inflammatory bowel diseases.
Péter Bacsur et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.